Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Medivir AB ( (SE:MVIR) ).
Medivir’s annual general meeting approved the 2025 accounts, discharged the board and CEO from liability, and decided that the year’s result will be carried forward, while setting total annual board remuneration at up to SEK 1,005,000 and reappointing Grant Thornton Sweden AB as auditor. Shareholders confirmed a four-member board with Anders Hallberg re-elected as chair, authorized the board to issue new shares of up to 20 percent of the post-issue share capital to secure flexible funding, and adopted a share price-related incentive programme for directors, backed by a resolution allowing transfer of own shares to hedge costs for existing and new share-based schemes.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Swedish biopharmaceutical company that develops innovative therapies targeting areas of high unmet medical need. Its lead drug candidates include fostrox, a precision chemotherapy for liver cancer, and MIV-711 for Osteogenesis Imperfecta, both viewed as potential blockbuster assets that underpin Medivir’s value proposition on Nasdaq Stockholm’s Small Cap segment.
Average Trading Volume: 10,943,631
Technical Sentiment Signal: Sell
Current Market Cap: SEK980.4M
For detailed information about MVIR stock, go to TipRanks’ Stock Analysis page.